Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Research
Return to: PBR Home | Contract Research & Services | Contract Research | News
Search Refinements

Contract Research News

View news from other Pharmaceutical sectors:
91-105 of 2107 results
AstraZeneca collaborates with Moderna, Incyte for new cancer treatments
By PBR Staff Writer
AstraZeneca has signed collaborations with Moderna Therapeutics and Incyte to develop new cancer treatments.
Contract Research & Services > Contract Research > News
Pfizer invests $46m into four early-stage research companies
By PBR Staff Writer
Pfizer has infused $46m into four early-stage research companies working on Conditionally Active Biologics (CABs), immuno-oncology, neurodegenerative technologies and gene therapy.
Contract Research & Services > Contract Research > News
PPD to support Moderna in clinical development of mRNA therapeutics
By PBR Staff Writer
Moderna Therapeutics has selected Pharmaceutical Product Development (PPD) as its clinical development partner for messenger RNA (mRNA) based drug development projects.
Contract Research & Services > Contract Research > News
Peregrine, NCCN partner to evaluate novel cancer treatment combinations with bavituximab
Peregrine Pharmaceuticals has announced a new research collaboration with the National Comprehensive Cancer Network (NCCN) to expand the company's ongoing clinical research and development of bavituximab for the treatment of a range of tumors.
Contract Research & Services > Contract Research > News
Baxalta, Symphogen form immuno-oncology collaboration
By PBR Staff Writer
US biopharmaceutical firm Baxalta has signed an agreement worth up to $1.6bn with Danish biotechnology company Symphogen to develop cancer drugs.
Contract Research & Services > Contract Research > News
Merck, Pfizer and Syndax to investigate avelumab and entinostat combination for ovarian cancer
By PBR Staff Writer
Merck and Pfizer have agreed to partner with Syndax Pharmaceuticals to evaluate a therapy to treat ovarian cancer.
Contract Research & Services > Contract Research > News
Lixte licenses LB-100 anti-cancer compound to Taipei Medical University
By PBR Staff Writer
Lixte Biotechnology has granted an exclusive license of its lead anti-cancer compound, LB-100, to Taipei Medical University (TMU).
Contract Research & Services > Contract Research > News
Bayer, CRISPR to create JV to develop new gene therapies
By PBR Staff Writer
Bayer and CRISPR Therapeutics have agreed to establish a joint venture (JV) to develop new treatments for curing blood disorders, blindness and congenital heart disease.
Contract Research & Services > Contract Research > News
Arsia Therapeutics, Biogen sign research collaboration to develop subcutaneous biologics
Arsia Therapeutics, a Cambridge based company, has announced a collaboration with Biogen.
Contract Research & Services > Contract Research > News
UCLA, Bristol-Myers Squibb join hands for immuno-oncology research
By PBR Staff Writer
Bristol-Myers Squibb (BMS) and the University of California, Los Angeles (UCLA) have signed a collaboration agreement as part of immuno-oncology rare population malignancy (I-O RPM) research program in the US.
Contract Research & Services > Contract Research > News
AstraZeneca collaborates with Wallenberg Centre for Protein Research
AstraZeneca and its global biologics research and development arm, MedImmune, have formed a three-year collaboration with the newly established Wallenberg Centre for Protein Research (WCPR).
Contract Research & Services > Contract Research > News
BMS establishes Center for Molecular Synthesis in collaboration with Princeton University
Bristol-Myers Squibb (BMS) and the Department of Chemistry at Princeton University today announced a new research collaboration, which includes the establishment of the Center for Molecular Synthesis (BMS-CMS).
Contract Research & Services > Contract Research > News
Amgen, Merck collaborate for two cancer immunotherapy trials
By PBR Staff Writer
Amgen and Merck have collaborated to evaluate a class of drugs that use the body’s immune system to fight cancer.
Contract Research & Services > Contract Research > News
Morphotek, Wisconsin university to study immunosuppressive effects of CA125 tumor antigen
Morphotek, a subsidiary of Eisai, has entered into a collaborative research agreement with University of Wisconsin-Madison (UW-Madison) to elucidate the immunosuppressive effects of the CA125 tumor antigen on the investigational monoclonal antibody farletuzumab.
Contract Research & Services > Contract Research > News
Zymeworks, GSK sign antibody collaboration deal
By PBR Staff Writer
Zymeworks has signed a collaboration and license agreement with GlaxoSmithKline (GSK) to develop and commercialize new Fc-engineered monoclonal and bi-specific antibody therapeutics.
Contract Research & Services > Contract Research > News
91-105 of 2107 results